BTIG raised the firm’s price target on Insulet (PODD) to $330 from $310 and keeps a Buy rating on the shares after its Q1 earnings beat. The company is well-positioned on macro uncertainty, with potential exemption since most of its U.S. product is made in its Acton, MA facility, the analyst tells investors in a research note. Tariffs have a 50 bps impact on gross margins this year, but Insulet is able to more than offset this and raised its gross margin guide by 50 bps instead while holding its already-impressive operating margin outlook to leave room for investments, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Strong Growth and Strategic Expansion Under New Leadership
- Insulet’s Strong Financial Performance and Growth Potential Drive Buy Rating
- Insulet’s Strong Financial Performance and Promising Future: A Buy Recommendation by Josh Jennings
- Insulet Corporation Reports Strong Q1 2025 Growth
- Closing Bell Movers: Pinterest jumps 15%, Toast up 7% after earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue